Article Text
PostScript
Letter
Immunomodulation with regulatory T cells and Fas-ligand ameliorate established inflammatory colitis
Statistics from Altmetric.com
Footnotes
-
Contributors All authors contributed to production of the data and preparation of the letter.
-
Funding This work was supported by grants from the Frankel Trust for Experimental Bone Marrow Transplantation.
-
Competing interests The SA-FasL protein and ProtEx technology described in this manuscript are licenced from UofL by ApoImmune, Inc, Louisville, KY, in which ESY has significant equity interest in the Company. The other authors disclosed no potential competing interests.
-
Provenance and peer review Not commissioned; internally peer reviewed.